Brought to you by 
Cubist and Syrrx look for anti-infectives
Aug 2001
Executive Summary
Cubist (anti-infectives) and Syrrx (protein structure) will combine their respective technologies to look for new anti-infectives, including antibiotics to fight bacteria resistant to current drugs.
Deal Industry
-
Biotechnology
- Drug Discovery Tools
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Includes Equity
- Includes Contract
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cubist and Syrrx look for anti-infectives
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice